TechsoMed is a Rehovot, Israel–based medical imaging software company developing the BioTrace platform, an AI and algorithm-powered system for real-time tissue viability imaging. Its first product, BioTraceIO, is primarily targeting liver tumor ablation procedures and is in clinical validation. The company is pursuing FDA De Novo clearance for its BioTrace system, with approval anticipated sometime in 2022 according to the article. BioTrace is designed for multi-clinical applications including oncology (tumor ablation), cardiology (heart arrhythmia) and pain management (radiofrequency neurotomy). TechsoMed collaborates with medical centers worldwide and has established a Japan subsidiary to support commercialization in Japan and other Asian markets. The company is led by CEO Yossi Abu. Techsomed is a biotech company developing ultrasound-based real-time monitoring systems for thermal ablation procedures. Its BioTrace™ system integrates with standard ultrasound devices and uses proprietary AI and image analysis to track the target tissue’s unique biological signature as it responds to heat. That signature is used to visually simulate the post 24-hour thermal effect in real time, enhancing the surgeon’s level of control and accuracy during the procedure. The company is based in Rehovot, Israel. Techsomed secured $2.6M in funding in a round led by Johnson & Johnson Innovation – JJDC, with participation from Screen Holdings, AMIT‑Technion (the Alfred Mann Institute), NextLeap Ventures and Axil Capital. It intends to use the funds for further development toward obtaining FDA, PMDA and CE regulatory approval.

Total raised

$10M

Funding rounds

2

Latest round

Series B

Latest activity

Mar 2021